Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of Arkansas |
---|---|
Information provided by: | University of Arkansas |
ClinicalTrials.gov Identifier: | NCT00090493 |
The hope is that the peptide vaccines will stimulate the immune system to attack and kill the myeloma cells. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Biological: MAGE-A3 |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | UARK 2003-26, A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination With DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma |
Estimated Enrollment: | 100 |
Study Start Date: | November 2003 |
Estimated Study Completion Date: | January 2013 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |
University of Arkansas for Medical Sciences/MIRT | Recruiting |
Little Rock, Arkansas, United States, 72205 | |
Contact: Cherie L Harless 501-296-1503 ext 1463 HarlessCherieL@uams.edu | |
Contact: Mark A Mosby, BS, CCRP 501-296-1503 ext 1543 mamosby@uams.edu | |
Sub-Investigator: Athanasios Fassas, M.D. | |
Sub-Investigator: Bart Barlogie, M.D., Ph.D. | |
Principal Investigator: Guido Tricot, M.D., Ph.D. | |
Sub-Investigator: Elias Anaissie, M.D. | |
Principal Investigator: Frits Van Rhee, M.D., Ph.D. | |
Sub-Investigator: Maurizio Zangari, M.D. | |
Sub-Investigator: Raymond Thertulien, M.D., Ph.D. | |
Sub-Investigator: Michele H Fox, M.D, Ph.D. | |
Sub-Investigator: John Shaughnessy, Ph.D. | |
Sub-Investigator: Edgardo Angtuaco, M.D. | |
Sub-Investigator: Eren Erdem, M.D. | |
Sub-Investigator: Ronald Walker, M.D. | |
Sub-Investigator: Susann Szmania, BS | |
Sub-Investigator: Elias Kiwan, M.D. | |
Sub-Investigator: Somashekar Krishna, M.D. | |
Sub-Investigator: Nidhi Jain, M.D. | |
Sub-Investigator: Mauricio Pineda-Roman, M.D. |
Principal Investigator: | Frits van Rhee, M.D., Ph.D. | Myeloma Institute for Research & Therapy |
Responsible Party: | University_of_Arkansas ( Frits van Rhee, M.D., Ph.D., MRCP(UK), FRCPath ) |
Study ID Numbers: | UARK 2003-26 |
Study First Received: | August 26, 2004 |
Last Updated: | December 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00090493 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Myeloma Mage-A3 Transplant Peptide |
DTPACE vaccines Immunotherapy NY-ESO-1 |
Immunoproliferative Disorders Hemorrhagic Disorders Hematologic Diseases Blood Protein Disorders Blood Coagulation Disorders Adjuvants, Immunologic |
Vascular Diseases Paraproteinemias Lymphoproliferative Disorders Hemostatic Disorders Neoplasms, Plasma Cell Multiple Myeloma |
Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Blood Protein Disorders Hematologic Diseases Vascular Diseases Paraproteinemias |
Hemostatic Disorders Multiple Myeloma Neoplasms Hemorrhagic Disorders Cardiovascular Diseases Lymphoproliferative Disorders Neoplasms, Plasma Cell |